From a risk-stratification standpoint, children with mild hemophilia A (factor VIII typically 5-40-50%) may be treated safely in ambulatory settings when procedures are triaged by invasiveness, factor levels are optimized for surgery, and teams are prepared with a bleeding action plan [11]. This evidence concerns the gene COX8A and hemophilia A.